Notably, Nandula and colleagues demonstrated that the amelioration of metabolic, CV and renal parameters of T2DM patients after canagliflozin therapy, a SGLT2 inhibitor, was associated with the improvement of CD34+ HSPCs function [32]. Here, CD34 is linked to type 2 diabetes mellitus.